A new study at Montefiore Einstein is evaluating tabelecleucel, a cellular immunotherapy, for patients with Epstein-Barr virus (EBV) associated diseases. The Phase 2 clinical trial is led by David M. Loeb, MD, PhD, Chief of Pediatric Hematology, Oncology and Cellular Therapy at the Children's Hospital at Montefiore Einstein and Professor of Pediatrics and Developmental and Molecular Biology at the Albert Einstein College of Medicine. The multicenter study, sponsored and led by Atara Biotherapeutics, offers hope for patients with challenging EBV-related conditions, including lymphoproliferative diseases and rare sarcomas that have limited treatment options.

EBV-associated diseases represent a significant clinical challenge, particularly in immunocompromised patients, where the virus can cause life-threatening lymphoproliferative disorders and rare malignancies. Traditional treatment approaches often fall short in these vulnerable populations, creating an urgent need for innovative therapeutic strategies. As a leading academic medical center with extensive clinical expertise, Montefiore Einstein is well-positioned to advance this critical research.

The study targets patients with relapsed and/or refractory disease or those newly diagnosed where standard first-line therapy is inappropriate. The cellular immunotherapy approach being investigated could provide new treatment options for patients facing these complex conditions. This comprehensive trial design allows for systematic assessment of efficacy across different disease cohorts, potentially benefiting diverse patient populations with limited therapeutic options.

The multicohort study encompasses five distinct EBV patient populations using an adaptive two-stage design. Each cohort initially enrolls eight evaluable participants, with potential expansion based on interim analysis results. This protocol also allows for Human Leukocyte Antigen (HLA) restriction switching, enabling administration of tabelecleucel with up to four different HLA restrictions for participants who don't initially respond to treatment. For more details on this study, visit https://clinicaltrials.gov/study/NCT04554914.